Rubicon Founders
Rubicon Founders describes itself as an entrepreneurial healthcare investment firm focused on building and growing transformational companies. Its stated approaches include ground-up company creation, platform and special-opportunity investing, and operating partnership.
What stands out about Rubicon Founders
Rubicon Founders focuses on healthcare businesses and combines investment with company building and operating partnership. Its official portfolio page identifies representative healthcare investments and excludes exploratory seed investments below $5 million from the displayed list, while the cited portfolio page does not publish universal fund, valuation, revenue, EBITDA, or transaction-size criteria.[1][2][3][4][11]
What does Rubicon Founders invest in?
Rubicon Founders describes itself as an entrepreneurial healthcare investment firm focused on building and growing transformational companies. The firm states that it invests in and partners to build meaningful businesses that create enduring value by transforming healthcare delivery.
Adam Boehler is identified as the founder and CEO. Rubicon’s materials also present the firm as both an investor and an operating partner that builds companies and works with portfolio-company leaders.[1][2][3]
Rubicon describes a ground-up approach in which data-driven processes are used to identify competitive advantage and are combined with mission-driven teams. It also describes a platform and special-opportunity approach that partners with exceptional healthcare companies and focuses on unique healthcare assets that it believes pioneer healthcare solutions.
The firm therefore presents two stated pathways: building a business from the ground up and investing in or partnering with existing healthcare companies and assets.[3]
Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.
What should a business owner evaluate before considering a transaction with Rubicon Founders?
An owner evaluating Rubicon should distinguish between the firm’s ground-up company-building model and its platform or special-opportunity approach. Rubicon’s stated healthcare specialization and operating-partner orientation indicate that discussions may involve both investment capital and company-building or operating support.
Because the cited materials do not disclose standard ownership percentages, transaction-size parameters, purchase-price terms, or consideration terms, an owner should obtain transaction-specific detail on ownership, governance, capital commitments, follow-on capital, investment horizon, transaction structure, and any rollover equity, earn-out, fee, or management-equity provisions. The owner should also clarify whether the opportunity would be treated as a platform investment, special opportunity, or ground-up company creation.[3][4]
What ownership percentage and governance rights would Rubicon seek in the proposed transaction
Would the proposed opportunity be structured as a platform investment, special opportunity, or ground-up company creation
What capital would be committed, and what follow-on capital would be available
What companies does Rubicon Founders target?
The official portfolio page states that exploratory seed investments below $5 million are excluded from the displayed list. The cited portfolio page does not publish a universal fund size, target enterprise-value range, revenue range, EBITDA range, or transaction-size range.[4]
Rubicon’s official portfolio spans healthcare businesses involved in value-based nephrology, hospice, home health, primary care, pediatrics, professional liability insurance, physician practice management, clinical research, behavioral health, infusion, oncology, and provider-network management.[4]
Rubicon Founders’ headquarters is identified as Nashville, Tennessee. Its launch materials describe a focus on transforming how healthcare is delivered in America.[2][5]
Rubicon describes platform investing and special-opportunity investing as approaches for partnering with exceptional healthcare companies and unique healthcare assets. Its separate ground-up model uses data-driven processes and mission-driven teams to create businesses. The sources cited for this profile do not establish a separate add-on investment framework.[3]
Representative official portfolio examples include US Heart & Vascular, Cadre Hospice, Honest Health, and Imagine Pediatrics. US Heart & Vascular is described as a physician practice management platform focused on enabling independent cardiologists to grow while improving patient care and reducing healthcare-system costs. Cadre Hospice is described as a next-generation pre-hospice and hospice provider.
Honest Health is described as a platform that partners with primary-care doctors to improve care experience and reduce costs for people with Medicare. Imagine Pediatrics is described as a tech-enabled pediatric medical group delivering 24/7 virtual and in-home care through value-based care arrangements.[4][6][7][8][9]
The official portfolio page identifies current representative healthcare portfolio examples, including US Heart & Vascular, Cadre Hospice, Honest Health, and Imagine Pediatrics. An official Rubicon technology article states that Imagine Pediatrics was launched by Rubicon in 2023.
The cited portfolio and individual portfolio pages do not disclose acquisition dates, transaction values, ownership percentages, or consideration terms for the identified portfolio examples.[4][6][7][8][9][10]
What is not clear from Rubicon Founders's public investment criteria?
The official portfolio page states that its displayed investments are representative, excludes exploratory seed investments below $5 million, and directs readers to contact Rubicon for a complete list. That page does not publish a universal fund size, target enterprise-value range, revenue range, EBITDA range, or transaction-size range.
The cited portfolio and individual portfolio pages do not disclose acquisition dates, transaction values, ownership percentages, or consideration terms for the identified portfolio examples. The cited Terms of Service page does not identify a legal-entity form or state a firm-level broker-dealer, investment-adviser, or other financial-regulatory registration status for Rubicon Founders.[4][11]
Questions to ask when evaluating Rubicon Founders as a buyer or investment partner
What ownership percentage and governance rights would Rubicon seek in the proposed transaction?
Would the proposed opportunity be structured as a platform investment, special opportunity, or ground-up company creation?
What capital would be committed, and what follow-on capital would be available?
What investment horizon and exit expectations would apply?
Which operating partners would support the company, and what role would they have?
How would the proposed structure address physician ownership, regulatory compliance, payer risk, and clinical-governance issues?
What transaction fees, rollover-equity expectations, earn-outs, or management-equity terms would apply?
Sources & research notes
- Official website / firm overview
- Official website / firm overview
- Investment strategy
- Industry / market focus
- Geography / market coverage
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Structure / regulatory context
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.